ARTL vs. AYTU, TLPH, FLGC, TCRT, GLYC, GLTO, NERV, TNXP, ORGS, and TRAW
Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Aytu BioPharma (AYTU), Talphera (TLPH), Flora Growth (FLGC), Alaunos Therapeutics (TCRT), GlycoMimetics (GLYC), Galecto (GLTO), Minerva Neurosciences (NERV), Tonix Pharmaceuticals (TNXP), Orgenesis (ORGS), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical preparations" industry.
Artelo Biosciences (NASDAQ:ARTL) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
Artelo Biosciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Artelo Biosciences' return on equity.
In the previous week, Aytu BioPharma had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Aytu BioPharma and 3 mentions for Artelo Biosciences. Aytu BioPharma's average media sentiment score of 1.66 beat Artelo Biosciences' score of 0.92 indicating that Aytu BioPharma is being referred to more favorably in the news media.
Artelo Biosciences has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.
0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 6.9% of Artelo Biosciences shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Aytu BioPharma received 217 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 73.08% of users gave Artelo Biosciences an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote.
Artelo Biosciences has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.
Artelo Biosciences currently has a consensus target price of $5.00, indicating a potential upside of 264.96%. Aytu BioPharma has a consensus target price of $5.00, indicating a potential upside of 58.73%. Given Artelo Biosciences' higher probable upside, equities analysts plainly believe Artelo Biosciences is more favorable than Aytu BioPharma.
Summary
Aytu BioPharma beats Artelo Biosciences on 8 of the 15 factors compared between the two stocks.
Get Artelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artelo Biosciences Competitors List
Related Companies and Tools
